fbpx Yourgene Health plc - Home
003-news.jpg
001-news.jpg
DSC00185r.jpg
002-news.jpg
004-news.jpg
previous arrow
next arrow

Please find below the latest news from Yourgene Health. We also share this news across social media networks.

  • 28 September 2021 - AGM Statement Investor presentation +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    AGM Statement
    Investor presentation

    Manchester , UK - 28 September 2021 : Yourgene (AIM: YGEN), a leading international molecular diagnostic group, will be holding its Annual General Meeting (AGM) at 4:00pm today.  In-person registration for this meeting is now closed due to COVID-19 protocols in place but investors can still attend via the Investor Meet Company website as described at the end of this notice.

    At the meeting Adam Reynolds, Non-executive

    Read More
  • 10 September 2021 - Further re: DHSC contract secured to support COVID-19 surge testing +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Further re: DHSC contract secured to support COVID-19 surge testing

    Manchester, UK 10 September 2021: Yourgene (AIM: YGEN), a leading international molecular diagnostic group, announces that a Contract Award Notice has been published in relation to its contract with the Department of Health & Social Care (“DHSC”) for the provision of laboratory capacity to the NHS Test and Trace Programme for COVID-19 testing, as announced

    Read More
  • 1 September 2021 - Yourgene Genomic Services receive ISO 15189:2012 accreditation +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Yourgene Genomic Services receive ISO 15189:2012 accreditation
    Validating its COVID-19 testing and sequencing services, providing assurance of compliance to international standards to deliver quality levels of performance and competence

    Manchester, UK – 1 September 2021: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces that following assessments by the UK accreditation service (UKAS), it has received ISO 15189:2012 accreditation for its COVID-19 testing and sequencing services,

    Read More
  • 1 September 2021 - Notice of AGM and Annual Report 2021 +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Notice of AGM and Annual Report 2021
    Investor presentation

    Manchester, UK 1 September 2021: Yourgene (AIM: YGEN), a leading international molecular diagnostic group, announces that the Notice of Annual General Meeting (“AGM”) and Form of Proxy will shortly be available on the Company’s website at: www.yourgene-health.com/investors/key-documents/shareholder-communications  and are being posted to those shareholders who have opted out of electronic communications.

    The Annual Report and Accounts

    Read More
  • 19 August 2021 - Yourgene’s COVID-19 testing investment reaps rewards DHSC contract secured to support COVID-19 surge testing +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Yourgene’s COVID-19 testing investment reaps rewards
    DHSC contract secured to support COVID-19 surge testing

    Manchester, UK 19 August 2021: Yourgene (AIM: YGEN), a leading international molecular diagnostic group, confirms that Yourgene Genomic Services (‘YGS’) has been awarded a contract for provision of laboratory capacity to the NHS Test and Trace Programme for COVID-19 testing by the Department of Health & Social Care (DHSC).

    In April

    Read More
  • 11 August 2021 - Earn-out Milestone, Issue of Equity & Total Voting Rights +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Earn-out Milestone, Issue of Equity & Total Voting Rights

    Manchester, UK 11 August 2021: Yourgene (AIM: YGEN), a leading international molecular diagnostic group, announces an issue of equity pursuant to the terms of the acquisition of Coastal ® Genomics Inc. ("Coastal") which completed in August 2020 (the “Acquisition”).

    Under the terms of the Coastal acquisition, a second strategic partnership Coastal Genomics’ Ranger ® technology was announced on

    Read More
  • 11 August 2021 - Audited Final results and unaudited Q1 business update +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Audited Final results and unaudited Q1 business update

    Manchester, UK – 11 August 2021: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces its full year financial results for the year ended 31 March 2021 (“FY21”), and provides a business update after its first trading quarter of the current financial year (Q1).

    The FY21 results, delivered in-line with prior guidance, reflect resilient revenue growth through the

    Read More
  • 21 June 2021 - Second Strategic Partner for Coastal Genomics +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Second Strategic Partner for Coastal Genomics

    Manchester, UK – 21 June 2021: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces that Yourgene Health Inc., the Company’s wholly-owned US subsidiary, has signed a Master Supply Agreement (“MSA”) (the “Agreement”) with a leading US laboratory services provider (“the Partner”). The Agreement provides the Partner with non-exclusive use of the Group’s Ranger TM Technology, which was acquired with

    Read More
  • 18 June 2021 - Contract Award for the supply of DPYD testing kits to NHS Wales +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Contract Award for the supply of DPYD testing kits to NHS Wales
    Estimated to be worth £232,000 across two years

     

    Manchester, UK –  June 2021: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces it has been awarded the contract to supply its Elucigene DPYD testing kits to NHS Wales. The contract award is for two years (for a period of 12 months with

    Read More
  • 9 June 2021 - Multi-year licence and supply agreement with leading US precision medicine company +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Multi-year licence and supply agreement with leading US precision medicine company

    Manchester, UK – 9 June 2021: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces it has entered into a licence and supply agreement (the “Agreement”) with a leading US precision medicine company (the “Partner”) for an initial term of three years commencing  1 April 2022. The Agreement grants the Partner a non-exclusive licence to

    Read More
  • 19 May 2021 - Distribution Partnership for the Middle East and Africa +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Distribution Partnership for the Middle East and Africa
    Yourgene and Alliance Global launch partnership across multiple territories

    Manchester, UK – 19 May 2021: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces that it is launching a Distribution Partnership with Dubai-headquartered Alliance Global FZ LLC (‘AGBL’ or ‘Alliance Global’) across a broad range of territories in the Middle East and Africa to expand the Company’s geographical

    Read More
  • 18 May 2021 - Launch of IONA® Care NIPT service offering +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Launch of IONA ® Care NIPT service offering
    Extended clinical menu to screen SCAs and AAs for pregnant women

    Manchester, UK – 18 May 2021: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces the launch of IONA ® Care, a non-invasive prenatal test (NIPT) service offering, with an extended clinical menu measuring the likelihood that a pregnant woman is carrying a fetus with sex chromosome aneuploidies (SCA

    Read More
  • 17 May 2021 - Further testing service agreement for MyHealthChecked plc +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Yourgene Genomic Services to support MHC’s second Boots agreement for Day 2 & Day 8 testing
    for international arrivals to the UK 

    Manchester, UK – 17 May 2021: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces that its partner MyHealthChecked plc (AIM:MHC) (“MyHealthChecked”) has signed a second COVID-19 testing services agreement, to support the supply of the MyHealthChecked™ COVID-19 at-home nasal swab kit, PCR laboratory

    Read More
  • 29 April 2021 - Full year Trading update +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Full year Trading update
    10% year-on-year revenue growth

    Manchester, UK – 29 April 2021: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces a trading update for the financial year ended 31 March 2021 (“FY 2021”).

    Yourgene reports unaudited revenues for FY 2021 of £18.3m (FY 2020: £16.6m), up 10% compared to the previous year.  This is in line with recently issued guidance and reflects

    Read More
  • 26 April 2021 - Further National Microbiology Framework contract awards +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Further National Microbiology Framework contract awards

    Successful tenders under Lots 2 & 3 valued at a total of £4bn
    Yourgene one of only three companies to have been successfully awarded under all four lots

    Manchester, UK – 26 April 2021: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces that Public Health England (“PHE”) has confirmed that Yourgene has been successful with its tenders under PHE’s

    Read More
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
Pregnant lady sitting at table with Laptop

Media & Investor Relations
Walbrook PR Ltd
4 Lombard Street
London
EC3V 9HD
yourgene@walbrookpr.com
T : +44 (0)20 7933 8780

Two business people looking at computer screen